

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	6	514/12.ccls. and "systemic lupus erythematosus"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:14
L2	0	514/12.ccls. and "systemic lupus erythematosus" SAME peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:14
L3	5	514/12.ccls. and "systemic lupus erythematosus" and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:33
L4	2	"20050008634".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:32
L5	0	514/13.ccls. and "systemic lupus erythematosus" and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:33
L7	0	"530/326".ccls. and "systemic lupus erythematosus" and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:34
L8	0	530/326.ccls. and "systemic lupus erythematosus" and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:38
L9	0	424/1.69.ccls. and "systemic lupus erythematosus" and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:38
L10	1	424/131.1.ccls. and "systemic lupus erythematosus" and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:52
L13	1	"200267848".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 20:43
L14	2	"20040127408".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 20:44

EAST Search History

S1	4	"systemic lupus erythrematosus". clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/10/01 19:14
S2	0	"systemic lupus erythrematosus". clm. and peptide.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/09/07 11:03
S3	1	"systemic lupus erythrematosus". clm. and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/09/07 11:05
S4	6	"systemic lupus erythrematosus" and peptide.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/09/07 11:05
S5	0	"systemic lupus erythrematosus".ti. and peptide.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/09/07 11:05
S6	0	"systemic lupus erythrematosus".ti. and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/09/07 11:05
S7	1	"systemic lupus erythrematosus". ab. and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/09/07 11:05
S8	2	"FSGYYWS"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/10/11 12:04
S9	2	"FSGYYWS" and lupus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/10/11 12:04
S10	2	"FSGYYWS" and lupus and carrier	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/10/11 12:04
S11	1	"FSGYYWS" and lupus and carrier and PEG	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/10/11 12:04
S12	1	"FSGYYWS" and lupus and carrier and glycol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/10/11 12:05

EAST Search History

S13	1	"FSGYYWS" and lupus and carrier and acetamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/10/11 12:05
S14	1	"FSGYYWS" and lupus and carrier and (PEG or demethyl or glycol or castor or methyl or pyrrolidinone or ester or cyclodextrin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 12:09
S15	10192	peptide and lupus and carrier and (PEG or demethyl or glycol or castor or methyl or pyrrolidinone or ester or cyclodextrin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 12:09
S16	7	lupus.ab. and peptide SAME carrier SAME (PEG or demethyl or glycol or castor or methyl or pyrrolidinone or ester or cyclodextrin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 12:11
S17	28	lupus.ab. and peptide SAME (PEG or demethyl or glycol or castor or methyl or pyrrolidinone or cyclodextrin) and carrier	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 13:23
S21	2	"9630057".did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 12:16
S22	1	"6613536".did. and lupus.ab. and peptide SAME (PEG or demethyl or glycol or castor or methyl or pyrrolidinone or cyclodextrin) and carrier	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 13:24
S23	1	"6613536".did. and lupus.ab. and peptide SAME (PEG or demethyl or glycol or castor or methyl or pyrrolidinone or cyclodextrin) and carrier and mg	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/11 13:24

SCORE Search Results Details for Application 10758397 and Search Result us-10-758-397a-6.rapbm.

[Score Home Page](#) [Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10758397 and Search Result us-10-758-397a-6.rapbm.

[start](#)

[Go Back to previous page](#)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2006, 15:08:25 ; Search time 181 Seconds
(without alignments)
48.625 Million cell updates/sec

Title: US-10-758-397A-6
Perfect score: 122
Sequence: 1 GYYWSWIRQPPGKGEWIG 19

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 2097797

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : Published_Applications_AA_Main:
1: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US07_PUBCOMB.pep:
2: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US08_PUBCOMB.pep:
3: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US09_PUBCOMB.pep:
4: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10A_PUBCOMB.pep:
5: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10B_PUBCOMB.pep:
6: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US11_PUBCOMB.pep:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description	
1	122	100.0	19	4	US-10-468-924-6	Sequence 6, Appl	102(e) 2004/0127408
2	122	100.0	19	4	US-10-758-572-1	Sequence 1, Appl	OPP
3	122	100.0	19	5	US-10-758-397-6	Sequence 6, Appl	APP
4	122	100.0	19	5	US-10-758-397-18	Sequence 18, Appl	APP
5	122	100.0	20	4	US-10-468-924-18	Sequence 18, Appl	
6	119	97.5	19	4	US-10-468-924-15	Sequence 15, Appl	
7	117	95.9	19	4	US-10-468-924-13	Sequence 13, Appl	
8	116	95.1	19	4	US-10-468-924-14	Sequence 14, Appl	
9	116	95.1	252	3	US-09-880-748-1326	Sequence 1326, Ap	
10	116	95.1	252	4	US-10-293-418-1326	Sequence 1326, Ap	
11	116	95.1	252	6	US-11-054-515-1326	Sequence 1326, Ap	
12	116	95.1	252	6	US-11-266-444-1326	Sequence 1326, Ap	
13	114	93.4	19	4	US-10-468-924-12	Sequence 12, Appl	
14	114	93.4	19	4	US-10-468-924-16	Sequence 16, Appl	

ALIGNMENTS

RESULT 1

US-10-468-924-6

; Sequence 6, Application US/10468924
; Publication No. US20040127408A1
; GENERAL INFORMATION:
; APPLICANT: YEDA Research and Development Co. Ltd
; APPLICANT: MOZES, Edna
; TITLE OF INVENTION: Synthetic Human Peptides and Pharmaceutical Compositions Comprising them
; TITLE OF INVENTION: for the Treatment of Systemic Lupus Erythematosus
; FILE REFERENCE: TEVA-003 PCT
; CURRENT APPLICATION NUMBER: US/10/468,924
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: IL 141647
; PRIOR FILING DATE: 2001-02-26
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Human
US-10-468-924-6

Query Match 100.0%; Score 122; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.7e-08;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
|||||||||||||||||||
Db 1 GYYWSWIRQPPGKGEIEWIG 19

RESULT 2

US-10-758-572-1

; Sequence 1, Application US/10758572
; Publication No. US20040180059A1
; GENERAL INFORMATION:
; APPLICANT: Cohen-Vered, Sharon
; APPLICANT: Naftali, Esmira
; APPLICANT: Weinstein, Vera
; APPLICANT: Gilbert, Adrian
; APPLICANT: Klinger, Ety
; TITLE OF INVENTION: PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS
; TITLE OF INVENTION: ERYTHEMATOSUS
; FILE REFERENCE: 2609/68518-A
; CURRENT APPLICATION NUMBER: US/10/758,572
; CURRENT FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A synthetic peptide of 19 amino acids based on the
; OTHER INFORMATION: complementarity-determining region 1 (CDR1) of the
; OTHER INFORMATION: human anti-dsDNA mAb denoted 16/6 Id
US-10-758-572-1

Query Match 100.0%; Score 122; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.7e-08;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
|||||||||||||||||||
Db 1 GYYWSWIRQPPGKGEIEWIG 19

RESULT 3

US-10-758-397-6

; Sequence 6, Application US/10758397
; Publication No. US20050008634A1
; GENERAL INFORMATION:
; APPLICANT: Cohen-Vered, et al., Sharon

; TITLE OF INVENTION: PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS
 ; TITLE OF INVENTION: ERYTHEMATOSUS
 ; FILE REFERENCE: 2609/68811-A
 ; CURRENT APPLICATION NUMBER: US/10/758,397
 ; CURRENT FILING DATE: 2004-01-14
 ; NUMBER OF SEQ ID NOS: 18
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 6
 ; LENGTH: 19
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic peptide based on CDR of mouse autoantibody
 US-10-758-397-6

Query Match 100.0%; Score 122; DB 5; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.7e-08;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
 |||||||
 Db 1 GYYWSWIRQPPGKGEIEWIG 19

RESULT 4
US-10-758-397-18

; Sequence 18, Application US/10758397
 ; Publication No. US20050008634A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Cohen-Vered, et al., Sharon
 ; TITLE OF INVENTION: PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS
 ; TITLE OF INVENTION: ERYTHEMATOSUS
 ; FILE REFERENCE: 2609/68811-A
 ; CURRENT APPLICATION NUMBER: US/10/758,397
 ; CURRENT FILING DATE: 2004-01-14
 ; NUMBER OF SEQ ID NOS: 18
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 18
 ; LENGTH: 19
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide based on the complementarity-determining region
 ; OTHER INFORMATION: 1 of human anti-dsDNA mAb denoted 16/6 Id
 US-10-758-397-18

Query Match 100.0%; Score 122; DB 5; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.7e-08;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
 |||||||
 Db 1 GYYWSWIRQPPGKGEIEWIG 19

RESULT 5
US-10-468-924-18

; Sequence 18, Application US/10468924
 ; Publication No. US20040127408A1
 ; GENERAL INFORMATION:
 ; APPLICANT: YEDA Research and Development Co. Ltd
 ; APPLICANT: MOZES, Edna
 ; TITLE OF INVENTION: Synthetic Human Peptides and Pharmaceutical Compositions Comprising them
 ; TITLE OF INVENTION: for the Treatment of Systemic Lupus Erythematosus
 ; FILE REFERENCE: TEVA-003 PCT
 ; CURRENT APPLICATION NUMBER: US/10/468,924
 ; CURRENT FILING DATE: 2003-08-21
 ; PRIOR APPLICATION NUMBER: IL 141647
 ; PRIOR FILING DATE: 2001-02-26
 ; NUMBER OF SEQ ID NOS: 30
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 18
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:

; OTHER INFORMATION: A peptide of SEQ ID NO: 11 wherein Xaa(1) is Thr Gly, Xaa(8) is A
; OTHER INFORMATION: rg, Xaa(10) is Pro, Xaa(12) is Gly, Xaa(13) is Lys, and Xaa(15) i
; OTHER INFORMATION: s Glu.
US-10-468-924-18

Query Match 100.0%; Score 122; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.8e-08;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
|||||||||||||||||||
Db 2. GYYWSWIRQPPGKGEIEWIG 20

RESULT 6

US-10-468-924-15

; Sequence 15, Application US/10468924
; Publication No. US20040127408A1
; GENERAL INFORMATION:
; APPLICANT: YEDA Research and Development Co. Ltd
; APPLICANT: MOZES, Edna
; TITLE OF INVENTION: Synthetic Human Peptides and Pharmaceutical Compositions Comprising them
; TITLE OF INVENTION: for the Treatment of Systemic Lupus Erythematosus
; FILE REFERENCE: TEVA-003 PCT
; CURRENT APPLICATION NUMBER: US/10/468,924
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: IL 141647
; PRIOR FILING DATE: 2001-02-26
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A peptide of SEQ ID NO: 11 wherein Xaa(1) is Gly, Xaa(8) is Lys,
; OTHER INFORMATION: Xaa(10) is Pro, Xaa(12) is Gly, Xaa(13) is Lys, and Xaa(15) is Gl
; OTHER INFORMATION: u.

US-10-468-924-15

Query Match 97.5%; Score 119; DB 4; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e-08;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
||||||:|||||||||||
Db 1 GYYWSWIQPPGKGEIEWIG 19

RESULT 7

US-10-468-924-13

; Sequence 13, Application US/10468924
; Publication No. US20040127408A1
; GENERAL INFORMATION:
; APPLICANT: YEDA Research and Development Co. Ltd
; APPLICANT: MOZES, Edna
; TITLE OF INVENTION: Synthetic Human Peptides and Pharmaceutical Compositions Comprising them
; TITLE OF INVENTION: for the Treatment of Systemic Lupus Erythematosus
; FILE REFERENCE: TEVA-003 PCT
; CURRENT APPLICATION NUMBER: US/10/468,924
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: IL 141647
; PRIOR FILING DATE: 2001-02-26
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A peptide of SEQ ID NO: 11 wherein Xaa(1) is Gly, Xaa(8) is Arg,
; OTHER INFORMATION: Xaa(10) is Pro, Xaa(12) is Gly, Xaa(13) is Lys, and Xaa(15) is Se
; OTHER INFORMATION: r.

US-10-468-924-13

Query Match 95.9%; Score 117; DB 4; Length 19;

SCORE Search Results Details for Application 10758397 and Search Result us-10-758-397a-6.rag.

[Score Home Page](#) [Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10758397 and Search Result us-10-758-397a-6.rag.

[start](#)

[Go Back to previous page](#)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2006, 14:46:16 ; Search time 196 Seconds
(without alignments)
44.322 Million cell updates/sec

Title: US-10-758-397A-6

Perfect score: 122

Sequence: 1 GYYWSWIRQPPGKGEWIG 19

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1000 summaries

Database : A_Geneseq_8:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

8: geneseqp2004s:*

9: geneseqp2005s:*

10: geneseqp2006s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	122	100.0	19	5	AAE27949	Aae27949 Human 16/
2	122	100.0	19	8	ADQ91214	Adq91214 Human com
3	122	100.0	19	8	ADR14722	Adr14722 Synthetic
4	122	100.0	20	5	AAE27961	Aae27961 Human 16/
5	119	97.5	19	5	AAE27958	Aae27958 Human 16/
6	117	95.9	19	5	AAE27956	Aae27956 Human 16/
7	116	95.1	252	5	ABP45315	Abp45315 Human BLY
8	116	95.1	252	7	ADG96142	Adg96142 Single ch
9	116	95.1	252	9	AED78195	Aed78195 Human B L
10	115	94.3	119	2	AAR54799	Aar54799 SpA-react

999	97	79.5	252	5	ABP45212	Abp45212 Human BLY
1000	97	79.5	252	7	ADG96039	Adg96039 Single ch

ALIGNMENTS

RESULT 1

AAE27949

ID AAE27949 standard; peptide; 19 AA.

XX

AC AAE27949;

XX

DT 27-DEC-2002 (first entry)

XX

DE Human 16/6Id mAb VH chain CDR1 peptide, hCDR1.

XX

KW Complementarity-determining region; CDR; variable heavy chain; VH; VL; variable light chain; SLE-associated response; immunosuppressive; SLE; systemic lupus erythematosus; dermatological; therapy; antiinflammatory; human.

XX

OS Homo sapiens.

XX

PN WO200267848-A2.

XX

PD 06-SEP-2002.

XX

PF 26-FEB-2002; 2002WO-IL000148.

XX

PR 26-FEB-2001; 2001IL-00141647.

XX

PA (YEDA) YEDA RES & DEV CO LTD.

XX

PI Mozes E;

XX

DR WPI; 2002-698624/75.

XX

PT New synthetic peptide useful for treating and ameliorating the clinical manifestations of systemic lupus erythematosus (SLE) by modulating SLE-associated responses.

XX

PS Claim 9; Page 6; 120pp; English.

XX

CC The invention relates to a synthetic peptide selected from a peptide of 12-30 amino acid residues with a sequence of, or found within, a complementarity-determining region (CDR) on the variable heavy (VH) or light (VL) chain of human monoclonal anti-DNA 16/6Id antibody (hCDR). The composition comprising the peptide is useful for the treatment of systemic lupus erythematosus (SLE) and amelioration of the clinical manifestations of the disease, particularly by modulating SLE-associated responses. The present sequence is human 16/6Id mAb VH chain CDR peptide

XX

SQ Sequence 19 AA;

Query Match 100.0%; Score 122; DB 5; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.3e-08;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEWIG 19
 ||||||| ||||||| |||||
 Db 1 GYYWSWIRQPPGKGEWIG 19

RESULT 2

ADQ91214

ID ADQ91214 standard; peptide; 19 AA.

XX

AC ADQ91214;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human complementarity determining region 1 peptide to treat SLE SeqID 1.

XX

KW acetate salt; human; complementarity determining region 1; CDR1; aqueous carrier; substituted beta-cyclodextrin;

KW hepta-(sulfobutyl ether)-beta-cyclodextrin; antiinflammatory;
KW dermatological; immunosuppressive; systemic lupus erythematosus; SLE;
KW interferon-gamma inhibitor;
KW transforming growth factor-beta secretion inhibitor.

XX
OS Homo sapiens.

XX
PN WO2004064788-A2.

XX
PD 05-AUG-2004.

XX
PF 14-JAN-2004; 2004WO-US000955.

XX
PR 14-JAN-2003; 2003US-0439950P.

XX
PA (TEVA-) TEVA PHARM IND LTD.
PA (TEVA-) TEVA PHARM USA INC.

XX
PI Cohen-Vered S, Naftali E, Weinstein V, Gilbert A, Klinger E;

XX
DR WPI; 2004-580637/56.

XX
PT Pharmaceutical composition useful for treating systemic lupus erythematosus, comprises carrier, composition of salt of human complementarity determining region 1 peptide, and substituted beta-cyclodextrin to dissolve peptide in carrier.

XX
PS Claim 1; SEQ ID NO 1; 76pp; English.

XX
CC This invention relates to a novel pharmaceutical composition comprising from 0.1-20 mg/ml of an acetate salt of a human complementarity determining region 1 (CDR1) peptide. Specifically, it refers to parenteral formulations of this peptide, such that the composition provides an aqueous carrier and a substituted beta-cyclodextrin present in an amount effective to dissolve the peptide in the aqueous carrier, wherein it shows a pH of between 4 and 9. The present invention further describes a peptide formulation comprising the peptide and 70-170mg/ml of hepta-(sulfobutyl ether)-beta-cyclodextrin dissolved together in the aqueous carrier such that the resulting pH solution is between 6.5 and 8.5. These compositions have been shown to exhibit antiinflammatory, dermatological and immunosuppressive activities and accordingly can be used to alleviate the symptoms of systemic lupus erythematosus (SLE) in human subjects. As such, they also act as inhibitors of interferon-gamma and transforming growth factor-beta secretion. This peptide sequence is the human CDR1 peptide of the invention.

XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 122; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.3e-08;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
Db 1 GYYWSWIRQPPGKGEIEWIG 19

RESULT 3

ADR14722

ID ADR14722 standard; peptide; 19 AA.

XX
AC ADR14722;

XX
DT 21-OCT-2004 (first entry)

XX
DE Synthetic peptide based on a human CDR1.

XX
KW complementarity determining region; CDR; heavy chain; light chain;
KW monoclonal anti-DNA 16/6 idiotype antibody; 16/6 Id antibody;
KW anti-DNA antibody; induces systemic lupus erythematosus; SLE.

XX
OS Homo sapiens.
OS Synthetic.

XX
PN WO2004064787-A2.

PD 05-AUG-2004.
XX
PF 14-JAN-2004; 2004WO-US000948.
XX
PR 14-JAN-2003; 2003US-0439918P.
XX
PA (TEVA-) TEVA PHARM IND LTD.
PA (TEVA-) TEVA PHARM USA INC.
XX
PI Cohen-Vered S, Naftali E, Weinstein V, Gilbert A, Klinger E;
XX
DR WPI; 2004-580636/56.
XX
PT Pharmaceutical composition for treating systemic lupus erythematosus (SLE), has salt of peptide corresponding to complementarity-determining region of heavy/light chain of anti-DNA 16/6 Id antibody that induces immune response to SLE.
XX
PS Claim 3; SEQ ID NO 6; 132pp; English.
XX
CC The specification describes a pharmaceutical composition, comprising a salt of a peptide with 12-30 consecutive amino acids having a sequence corresponding to an amino acid sequence found within complementarity-determining region (CDR) of the heavy or light chain of the human monoclonal anti-DNA 16/6 idiotype (16/6 Id) antibody, or a heavy or light chain of a pathogenic anti-DNA monoclonal antibody that induces systemic lupus erythematosus (SLE)-like disease response in mice. The composition is useful for treating SLE and for alleviating symptoms of SLE in a human subject. The present sequence represents a peptide based on a human CDR1, and designated compound 1. The present peptide is used in pharmaceutical compositions of the invention.
XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 122; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.3e-08;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEWIG 19
|||||||||||||||||||
Db 1 GYYWSWIRQPPGKGEWIG 19

RESULT 4
AAE27961
ID AAE27961 standard; peptide; 20 AA.
XX
AC AAE27961;
XX
DT 27-DEC-2002 (first entry)
XX
DE Human 16/6Id mAb VH chain CDR1 peptide mutant #1.
XX
KW Complementarity-determining region; CDR; variable heavy chain; VH; VL; variable light chain; SLE-associated response; immunosuppressive; SLE; systemic lupus erythematosus; dermatological; therapy; antiinflammatory; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200267848-A2.
XX
PD 06-SEP-2002.
XX
PF 26-FEB-2002; 2002WO-IL000148.
XX
PR 26-FEB-2001; 2001IL-00141647.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Mozes E;
XX
DR WPI; 2002-698624/75.
XX
PT New synthetic peptide useful for treating and ameliorating the clinical

④
Same as 1

PT manifestations of systemic lupus erythematosus (SLE) by modulating SLE-associated responses.
XX
PS Claim 8; Page 15; 120pp; English.
XX
CC The invention relates to a synthetic peptide selected from a peptide of 12-30 amino acid residues with a sequence of, or found within, a complementarity-determining region (CDR) on the variable heavy (VH) or light (VL) chain of human monoclonal anti-DNA 16/6Id antibody (hCDR). The composition comprising the peptide is useful for the treatment of systemic lupus erythematosus (SLE) and amelioration of the clinical manifestations of the disease, particularly by modulating SLE-associated responses. The present sequence is a mutant created by addition of Thr residue to the N-terminus of human 16/6Id mAb VH chain CDR peptide
XX
SQ Sequence 20 AA;

Query Match 100.0%; Score 122; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.8e-08;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYYWSWIRQPPGKGEIEWIG 19
|||||||||||||||||||
Db 2 GYYWSWIRQPPGKGEIEWIG 20

RESULT 5
AAE27958
ID AAE27958 standard; peptide; 19 AA.
XX
AC AAE27958;
XX
DT 27-DEC-2002 (first entry)
XX
DE Human 16/6Id mAb VH chain CDR1 peptide mutant, R8K.
XX
KW Complementarity-determining region; CDR; variable heavy chain; VH; VL; variable light chain; SLE-associated response; immunosuppressive; SLE; systemic lupus erythematosus; dermatological; therapy; antiinflammatory; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 8
FT /note= "Wild-type Arg is replaced with Lys"
XX
PN WO200267848-A2.
XX
PD 06-SEP-2002.
XX
PF 26-FEB-2002; 2002WO-IL000148.
XX
PR 26-FEB-2001; 2001IL-00141647.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Mozes E;
XX
DR WPI; 2002-698624/75.
XX
PT New synthetic peptide useful for treating and ameliorating the clinical manifestations of systemic lupus erythematosus (SLE) by modulating SLE-associated responses.
XX
PS Claim 8; Page 15; 120pp; English.
XX
CC The invention relates to a synthetic peptide selected from a peptide of 12-30 amino acid residues with a sequence of, or found within, a complementarity-determining region (CDR) on the variable heavy (VH) or light (VL) chain of human monoclonal anti-DNA 16/6Id antibody (hCDR). The composition comprising the peptide is useful for the treatment of systemic lupus erythematosus (SLE) and amelioration of the clinical manifestations of the disease, particularly by modulating SLE-associated responses. The present sequence is human 16/6Id mAb VH chain CDR mutant